Key features and details
- Selective D1-like dopamine receptor antagonist
- CAS Number: 125941-87-9
- Purity: > 99%
- Soluble in water to 100 mM
- Form / State: Solid
- Source: Synthetic
Product nameSCH 23390 hydrochloride, D1-like dopamine receptor antagonist
DescriptionSelective D1-like dopamine receptor antagonist
Selective D1-like dopamine receptor antagonist. Ki values are 0.2 (D1), 0.3 (D5), 1100 (D2), 800 (D3) and 3000 nM (D4). Some activity at 5-HT receptors (Ki values are 6.3 and 14.8 nM for 5-HT1C and 5-HT2C, respectively). Antipsychotic properties. Centrally active following subcutaneous administration.
Chemical name(R)-(+)-7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
Storage instructionsStore at +4°C. It is important to note that this product is reported to be light sensitive. Store In the Dark. Store under desiccating conditions.
Solubility overviewSoluble in water to 100 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab120597 has been referenced in 3 publications.
- Bocarsly ME et al. A Mechanism Linking Two Known Vulnerability Factors for Alcohol Abuse: Heightened Alcohol Stimulation and Low Striatal Dopamine D2 Receptors. Cell Rep 29:1147-1163.e5 (2019). PubMed: 31665630
- Spigolon G et al. cJun N-terminal kinase (JNK) mediates cortico-striatal signaling in a model of Parkinson's disease. Neurobiol Dis 110:37-46 (2018). PubMed: 29107639
- Iderberg H et al. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action. Exp Neurol 250:116-24 (2013). PubMed: 24029003